| GEORGETOWN UNIVERSITY Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136074 | SYSTEMS AND METHODS EMPLOYING LOW MOLECULAR WEIGHT GELATORS FOR CRUDE OIL, PETROLEUM PRODUCT OR CHEMICAL SPILL CONTAINMENT AND REMEDIATION - Low molecular weight gelators, methods of making such gelators, organogels comprising such gelators and systems and methods of using such gelators for the containment and/or remediation of a release and/or spill of a crude oil, a petroleum product and/or a chemical is described. In exemplary systems and methods, gels and/or emulsions formed from the combination and/or contact of such gelators and at least one of a crude oil, a petroleum product and a chemical from a release and/or spill into the environment can be used to recover these oils or chemicals while allowing the gelators to be recovered and reused to clean up or contain additional crude oil, petroleum products or chemicals. | 05-31-2012 |
| 20120134932 | Manganese-Oxo Clusters as Contrast Agents for Magnetic Resonance Imaging - Nanoparticles for use as magnetic resonance imaging contrast agents are described. The nanoparticles are made up of a polymeric support and a manganese-oxo or manganses-iron-oxo cluster having magnetic properties suitable of a contrast agent. The manganese-oxo clusters may be Mn-12 clusters, which have known characteristics of a single molecule magnet. The polymer support may form a core particle which is coated by the clusters, or the clusters may be dispersed within the polymeric agent. | 05-31-2012 |
| 20120128693 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF - Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis. | 05-24-2012 |
| 20120107833 | Antibody specific for a mammalian sphingosine kinase type 2 isoform protein and methods of use thereof - Polyclonal or monoclonal antibodies which are specific for a mammalian sphingosine kinase type 2 isoform protein and methods for detecting the presence of sphingosine kinase type 2 isoform using the antibodies. | 05-03-2012 |
| 20120065088 | SEQUENCE-SPECIFIC DETECTION OF NUCLEOTIDE SEQUENCES - A method for detecting the presence of a target nucleotide sequence in a sample of DNA is described herein in which a test sample comprising single stranded DNA is exposed to a DNA probe and a nicking endonuclease under conditions that would permit sequence-specific hybridization of the probe to a complementary target sequence. The probe comprises a sequence complementary to the target sequence to be detected and this sequence also includes a recognition sequence for the nicking endonuclease. If the sample contains the target sequence, the probe hybridizes to the target and is cleaved by the nicking endonuclease, which leaves the target intact. Observing the presence of probe cleaved by the nicking endonuclease indicates the presence of the target nucleotide sequence in the sample of DNA. | 03-15-2012 |
| 20120055045 | ORTHOTIC DEVICES - The present invention relates to orthotic devices and footwear. In particular, the present invention relates to orthotic devices comprising a wedge configured to be placed beneath a forefoot. | 03-08-2012 |
| 20120010487 | SYSTEMS AND METHODS FOR MONITORING HEALTH AND DELIVERING DRUGS TRANSDERMALLY - The present invention pertains to a system and method for transdermal sampling, comprising: at least one sampler for retrieving and transferring at least one analyte obtained transdermally from the skin of a subject; at least one detector system for identifying and quantifying said at least one analyte; and at least one logic module for (i) receiving and storing input data from said at least one detector, (ii) relating the input data to other data obtained from the subject, (iii) displaying output information, (iv) transmitting the output information to another system, and (v) controlling the operation of said at least one sampler and at least one detector. | 01-12-2012 |
| 20110317960 | DIRECT COUPLING OF OPTICAL SLOT WAVEGUIDE TO ANOTHER OPTICAL WAVEGUIDE - Devices, systems and techniques for directly coupling an optical slot waveguide to another optical waveguide without a taper waveguide region between the two optical waveguides. | 12-29-2011 |
| 20110301208 | VIRAL AND FUNGAL INHIBITORS - Novel classes of viral and fungal inhibitors are disclosed. These compounds are useful in treating, preventing, and/or ameliorating viral infections such as, for example, Hepatitis C Virus, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus, and fungal infections such as, for example, candidiasis. | 12-08-2011 |
| 20110269733 | Silent Desensitizers of Neuronal nAChR and Methods of Use Thereof - One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. | 11-03-2011 |
| 20110269178 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER - Disclosed are molecules and their synthesis. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo. | 11-03-2011 |
| 20110265008 | CLINICAL MANAGEMENT SYSTEM FOR CHRONIC ILLNESSES USING TELECOMMUNICATION - Patients with chronic illnesses resist using conventional automated healthcare management systems to supply necessary clinical data because such systems feel impersonal, preferring to actually visit a clinic where the patient interacts with various healthcare practitioners. In this invention, the patient interacts with a clinical management system via a series of initial GUI screens that replicate the experience of actually visiting the clinic. Additional screens allow the patient to submit clinical information, to communicate with that patient's healthcare practitioner and other healthcare practitioners, to access management information that aids the patient in managing that patient's chronic illness, and to access educational information regarding that chronic illness. The clinical management system may be used to manage a plurality of different chronic illnesses while providing a consistent look and feel to the screens. At least one appearance characteristic can be altered to indicate the particular chronic illness to which a screen applies. | 10-27-2011 |
| 20110256469 | Platinum Adlayered Ruthenium Nanoparticles, Method for Preparing, and Uses Thereof - A superior, industrially scalable one-pot ethylene glycol-based wet chemistry method to prepare platinum-adlayered ruthenium nanoparticles has been developed that offers an exquisite control of the platinum packing density of the adlayers and effectively prevents sintering of the nanoparticles during the deposition process. The wet chemistry based method for the controlled deposition of submonolayer platinum is advantageous in terms of processing and maximizing the use of platinum and can, in principle, be scaled up straightforwardly to an industrial level. The reactivity of the Pt(31)-Ru sample was about 150% higher than that of the industrial benchmark PtRu (1:1) alloy sample but with 3.5 times less platinum loading. Using the Pt(31)-Ru nanoparticles would lower the electrode material cost compared to using the industrial benchmark alloy nanoparticles for direct methanol fuel cell applications. | 10-20-2011 |
| 20110251294 | FAST RECOVERY OF THIXOTROPY BY ORGANOGELS WITH LOW MOLECULAR WEIGHT GELATORS - Low molecular weight gelators, methods of making such gelators, organogels comprising such gelators and methods of using such organogels are described. In exemplary methods, the gelators can be used in a variety of applications including the delivery of pharmaceutical active pharmaceutical ingredients, in food, cosmetics and consumer products, and in containing the unexpected release of chemical that occur for example in spills. | 10-13-2011 |
| 20110251193 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES - Novel classes of 1,2-benzisothiazolinone and isoindolinone compounds and compositions are disclosed. These compounds and compositions are useful in treating, preventing, and/or ameliorating viral, yeast, and fungal infections such as, for example, Hepatitis C Virus, Flavivirus infections, | 10-13-2011 |
| 20110230442 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS - Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [ | 09-22-2011 |
| 20110224207 | FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE - Methods of treating, preventing, and/or ameliorating a Flavivirus infection in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a Flavivirus inhibitor, e.g., a Flavivirus serine protease inhibitor. These methods are useful in treating, preventing, and/or ameliorating Flavivurs infections such as, for example, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus. | 09-15-2011 |
| 20110217389 | METHODS FOR TREATING HEAT STRESS AND RELATED COMPOSITIONS - Methods of treating, reducing, and/or preventing heat stress are provided. For example, provided is a method of treating or preventing heat stress in a subject comprising selecting a subject in need of heat stress treatment or prevention and administering an effective amount of one or more of astaxanthin and milk casein hydrolysate, or a derivative thereof to the subject. Also provided are methods of reducing the effects of a fever in a subject comprising administering an effective amount of one or more of astaxanthin, chromium and milk casein hydrolysate, or a derivative thereof, to the subject. Also provided are pharmaceutical compositions, comprising astaxanthin and one or more of chromium or milk casein hydrolysate. | 09-08-2011 |
| 20110213146 | Transition Metal-Catalyzed C-H Amination Using Unactivated Amines - One aspect of the invention relates to a method of animation or amidation, comprising the step of combining a substrate, comprising a reactive C—H bond, and an amine or amide, comprising a reactive N—H bond, in the presence of an oxidizing agent and a metal-containing catalyst, thereby forming a product with a covalent bond between the carbon of the reactive C—H bond and the nitrogen of the reactive N—H bond. | 09-01-2011 |
| 20110182890 | ANTI-PLEIOTROPHIN ANTIBODIES AND METHODS OF USE THEREOF - The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein. | 07-28-2011 |
| 20110130421 | Methods and Compositions for the Treatment of Chronic Renal Hypertension - Methods and compositions for the treating chronic renal hypertension in a subject comprising administering a therapeutically effective amount of at least one nitroxide-containing composition to the subject, particularly 4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl (Tempol). | 06-02-2011 |
| 20110123980 | SEQUENCE-SPECIFIC DETECTION OF NUCLEOTIDE SEQUENCES - A method for detecting the presence of a target nucleotide sequence in a sample of DNA is described herein in which a test sample comprising single stranded DNA is exposed to a DNA probe and a nicking endonuclease under conditions that would permit sequence-specific hybridization of the probe to a complementary target sequence. The probe comprises a sequence complementary to the target sequence to be detected and this sequence also includes a recognition sequence for the nicking endonuclease. If the sample contains the target sequence, the probe hybridizes to the target and is cleaved by the nicking endonuclease, which leaves the target intact. Observing the presence of probe cleaved by the nicking endonuclease indicates the presence of the target nucleotide sequence in the sample of DNA. | 05-26-2011 |
| 20110107253 | CLINICAL MANAGEMENT SYSTEM FOR CHRONIC ILLNESSES USING TELECOMMUNICATION - Patients with chronic illnesses resist using conventional automated healthcare management systems to supply necessary clinical data because such systems feel impersonal, preferring to actually visit a clinic where the patient interacts with various healthcare practitioners. In this invention, the patient interacts with a clinical management system via a series of initial GUI screens that replicate the experience of actually visiting the clinic. Additional screens allow the patient to submit clinical information, to communicate with that patient's healthcare practitioner and other healthcare practitioners, to access management information that aids the patient in managing that patient's chronic illness, and to access educational information regarding that chronic illness. The clinical management system may be used to manage a plurality of different chronic illnesses while providing a consistent look and feel to the screens. At least one appearance characteristic can be altered to indicate the particular chronic illness to which a screen applies. | 05-05-2011 |
| 20110104252 | ANTI-APOPTOTIC GENE SCC-S2 AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous leukemia, lung, lymphoblastic leukemia, and colorectal adenocarcinoma cells. | 05-05-2011 |
| 20110098504 | Histone Deacetylase Inhibitors and Methods of Use Thereof - The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention. | 04-28-2011 |
| 20110081295 | PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR EXPRESSION LEVEL AS AN INDEX OF ORGAN DAMAGE AND REGENERATION - The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy. | 04-07-2011 |
| 20110045100 | Antimalarial Quinolines and Methods of Use Thereof - One aspect of the invention relates to substitute quinolines with antimalarial activity, and compositions and kits comprising at least one of them. Another aspect of the invention relates to methods for the treatment or prevention or both of malaria comprising administering to a subject a therapeutically effective amount of such a compound. Importantly, a number of the compounds show excellent potency against both chloroquine-sensitive and chloroquine-resistant strains. | 02-24-2011 |
| 20110021885 | SUBDURAL ELECTRO-OPTICAL SENSOR - A subdural electro-optical sensor system may include a substrate to which is attached an array of electrodes, light emitters, and light detectors. The sensor system may be sufficiently thin, flexible, sterile and biocompatible to be positioned subdurally. | 01-27-2011 |
| 20100313286 | G protein-related kinase mutants in essential hypertension - Disclosed are methods for identifying individuals predisposed to essential hypertension and related conditions such as salt sensitivity by detecting the presence of polymorphic or mutant forms of the GRK4 gene, or its expression product. Also disclosed are methods for identifying polymorphic or mutant GRK4s in individuals known to be suffering from such conditions, as well as methods and compositions for conducting drug discovery and therapeutic intervention. | 12-09-2010 |
| 20100233156 | Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors - Provided herein are methods of treating an acute central nervous system injury in a subject. The methods comprise administering to the subject a γ or β secretase inhibitor, an Aβ antibody, or an immunogenic fragment of Aβ. | 09-16-2010 |
| 20100202964 | Organ Homing Genes of Cancer Metastases - Provided herein are methods that use liver targeting domains of colon cancer, such as for example PA28alpha, HNRNPA1, and/or KIAA1407, and the polynucleotides that encode them, for the prognosis, diagnosis, detection, staging and/or prediction of survival rates in individuals with colon cancer, whether the cancer has metastasized or not, as well as for imaging purposes and design of diagnostic and/or therapeutic methods. | 08-12-2010 |
| 20100196502 | Isoform Selective HDAC Inhibitors - One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising a an HDAC inhibitor of the invention. | 08-05-2010 |
| 20100175006 | SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT-RELATED INFORMATION - A system and method involves detecting operational social disruptive events on a global scale, assigning disease event staging and warnings to express data in more simplistic terms, modeling data in conjunction with linguistics analysis to establish responsive actions, generating visualization and modeling capabilities for communicating information, and modeling disease propagation for containment and forecasting purposes. | 07-08-2010 |
| 20100169987 | ANIMAL MODEL SIMULATING NEUROLOGIC DISEASE - The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having Alzheimer's Disease. In one embodiment, a four-week continuous infusion of a Fe | 07-01-2010 |
| 20100167994 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY - Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein. | 07-01-2010 |
| 20100151466 | DIAGNOSIS AND TREATMENT OF CERVICAL CANCER - In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers. | 06-17-2010 |
| 20100130579 | CANCER THERAPY - The present invention relates to methods of inducing expression of an epigenetically silenced gene, RASSF1A, in cells, particularly human cells, such as cancer cells. It also relates to methods of treating an individual, prophylactically or therapeutically, for cancer in which RASSF1A is epigenetically silenced. | 05-27-2010 |
| 20100120892 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF STAT5 IN PROSTATE CANCER CELLS - The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells. | 05-13-2010 |
| 20100111964 | PLEIOTROPHIN GROWTH FACTOR RECEPTOR FOR THE TREATMENT OF PROLIFERATIVE, VASCULAR AND NEUROLOGICAL DISORDERS - This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders. | 05-06-2010 |
| 20100081689 | Methods and Compositions for the Treatment of Iron Toxicity - Methods and compositions for the treatment of iron toxicity using nitroxides, particularly 4-hydroxy-2,2,6,6-tetramethyl- | 04-01-2010 |
| 20100069344 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS - The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-X | 03-18-2010 |
| 20100056806 | C-H Bond Amination and Olefin Aziridination with Beta-Diketiminato Copper Catalysts - One aspect of the present invention relates to a method for the transition metal (e.g., Cu(I)) mediated amidation of C—H bonds using electron-rich aliphatic azides. In certain embodiments, the methods are useful for the C—H insertion of nitrenes generated and stabilized by a β-diketiminato metal catalyst. In certain embodiments, said nitrenes are generated from organoazides, or by oxidation of the corresponding amine. Another aspect of the present invention relates to olefin aziridination using said β-diketiminato metal catalysts. In addition, the methods of the present invention include stereoselective C—H bond aminations and olefin aziridinatons. In certain embodiments, the methods are conducted in an aerobic environment. In certain embodiments, the present invention relates to the use of O | 03-04-2010 |
| 20100041142 | ANTI-APOPTOTIC GENE SCC-S2 AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous leukemia, lung, lymphoblastic leukemia, and colorectal adenocarcinoma cells. | 02-18-2010 |
| 20100015114 | PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR EXPRESSION LEVEL AS AN INDEX OF ORGAN DAMAGE AND REGENERATION - The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy. | 01-21-2010 |
| 20090286876 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS - The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof. | 11-19-2009 |
| 20090232815 | ANTIBODIES THAT BIND TO PLEIOTROPHIN GROWTH FACTOR RECEPTOR - This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders. | 09-17-2009 |
| 20090191261 | Antibody fragment-targeted immunoliposomes for systemic gene delivery - Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer. | 07-30-2009 |
| 20090169555 | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof - Nucleic acids encoding mouse and human sphingosine kinase type 2 isoforms, methods for detecting agents or drugs which inhibit or promote sphingosine activity and therapeutic agents containing peptides or antibodies to peptides encoded by such nucleic acids. | 07-02-2009 |
| 20090163543 | Histone Deacetylase Inhibitors and Methods of Use Thereof - One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention. | 06-25-2009 |
| 20090053299 | Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery - The present invention is in the fields of drug delivery, and specifically, cationic liposome-based vaccines. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of molecules to induce immune responses against viral antigens or to treat or prevent viral diseases. The specificity of the delivery system is derived from the targeting ligands. | 02-26-2009 |
